Galmed Pharmaceuticals Ltd (GLMD) Stock Analysis
Verdict: AVOID
Severe cash burn ($6.32M FCF loss in 2025) against a depleted $3.98M cash balance implies acute dilution risk within 8 months.
Investment score: 21/100
Analysis as of
Is Galmed Pharmaceuticals Ltd stock worth reviewing? AI model thesis
The AI model views GLMD as a high-risk microcap biotech facing imminent dilution. Pre-revenue status, severe multi-year share dilution, and cash burn outweigh clinical pipeline potential.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Galmed Pharmaceuticals Ltd opportunities and risks
What speaks for GLMD
- Aramchol Phase III or trial partnership catalyst
What speaks against GLMD
- Imminent dilutive capital raise due to 7.5-month cash runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GLMD | n/a | 0.0x | n/a | 0.0% | 0.0% | -178.6% |
| NRSN | n/a | 0.0x | n/a | 0.0% | 0.0% | -33.0% |
| EVGN | n/a | 3.3x | 0.2x | -14.2% | -696.3% | -272.7% |
| CLGN | n/a | 12.3x | n/a | -319.3% | -3376.3% | -241.8% |
| SLXN | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -8205.5% |
| SCNI | n/a | 0.5x | n/a | -252.4% | -177.0% | -933.9% |
| Peer median | n/a | 0.5x | n/a | -14.2% | -177.0% | -272.7% |
Frequently asked questions about Galmed Pharmaceuticals Ltd (GLMD)
Is GLMD stock a good investment?
The cached TradeMates AI model rates Galmed Pharmaceuticals Ltd as AVOID with an investment score of 21/100. The AI model views GLMD as a high-risk microcap biotech facing imminent dilution. Pre-revenue status, severe multi-year share dilution, and cash burn outweigh clinical pipeline potential. This is algorithmic model output, not personal investment advice.
Is GLMD stock a buy?
The TradeMates model verdict for GLMD is AVOID with an investment score of 21/100. Treat this as a model signal to review, not a personal buy recommendation.